^
    Back
    Association details:
    Biomarker:BRAF K601E
    Cancer:Non Small Cell Lung Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    J Thorac Oncol
    Title:

    Clinico-genomic features and targetable mutations in non-small cell lung cancers harboring BRAF non-V600E mutations: A multi-institutional genomic screening study (LC-SCRUM-Asia)

    Published date:
    08/03/2023
    Excerpt:
    ...one NSCLC patient with K601E showed good response to dabrafenib plus trametinib.
    DOI:
    https://doi.org/10.1016/j.jtho.2023.07.024